Paper identifies genes associated with risk for aggressive breast cancer

August 7, 2018, Oxford University Press
Three-dimensional culture of human breast cancer cells, with DNA stained blue and a protein in the cell surface membrane stained green. Image created in 2014 by Tom Misteli, Ph.D., and Karen Meaburn, Ph.D. at the NIH IRP.

A new study published in the Journal of the National Cancer Institute has identified specific genes associated with increased risk for triple-negative breast cancer, providing the basis for better risk management.

Triple-negative breast cancer is an aggressive type of cancer that cannot be treated using the most common therapies. It accounts for 15 percent of breast cancer in the Caucasian population and 35 percent in the African American population. It is also associated with high recurrence risk and poor five-year survival rate.

Germline genetic testing can identify women at increased risk of breast cancer by evaluating if there are genetic changes, often inherited from a parent, that increase the risk of certain cancers. However, it has been difficult to identify women at elevated risk of triple-negative breast cancer because only inherited mutations in BRCA1 (a human tumor suppressor gene discovered in 1990) have been linked to this subtype of breast cancer.

Here researchers performed genetic testing on 10,901 triple-negative breast cancer from two studies. For 8753 patients, 21 were tested, and for the remaining 2148 patients, 17 genes were tested.

Among the genes tested, researchers found that alternations in BARD1, BRCA1, BRCA2, PALB2, and RAD51D genes were associated with high risk for triple-negative breast cancer and greater than 20 percent lifetime risk for overall breast cancer among Caucasians. Researchers observed a similar trend among African Americans. In addition, mutations in BRIP1 and RAD51C were linked to more moderate risks of triple-negative disease.

This study is the first to establish which genes are associated with high lifetime risks of triple-negative breast cancer. While previous studies have found genetic variants in BARD1, BRIP1, PALB2, and RAD51C more frequently in triple-negative breast cancer patients than in patients with other breast cancer subtypes, the current study shows this in more detail and identifies a new specific and strong association between the susceptibility gene RAD51D and triple-negative breast cancer risk. The study's findings will now enable expanded to identify women at risk of this disease, potentially leading to better prevention strategies.

The new finding also suggests potential revisions to the National Comprehensive Cancer Network guidelines, which currently recommend only BRCA1/2 testing when a patient has a family history of breast cancer or someone is diagnosed at age 60 or younger. Based on a better understanding of gene-specific risks for triple-negative breast cancer from the study, it will be possible to establish guidelines for testing of other susceptibility genes; and women with genetic changes these genes should be able to receive better risk assessment.

"The results from our study showing that multiple genes cause increased risk of triple-negative breast should help in the clinical management of women found to have inherited mutations in these genes," said Fergus J. Couch, Ph.D., one of the authors of the study.

Explore further: Research helps refine role of gene variants in breast cancer risk

More information: Hermela Shimelis et al, Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing, JNCI: Journal of the National Cancer Institute (2018). DOI: 10.1093/jnci/djy106

Related Stories

Research helps refine role of gene variants in breast cancer risk

December 7, 2016
Inherited pathogenic variants in protein coding genes BARD1 and RAD51D increase a woman's likelihood of developing breast cancer, according to research conducted at Mayo Clinic and presented today at the 2016 San Antonio ...

Triple-negative breast cancer patients should undergo genetic screening

December 2, 2014
Most patients with triple-negative breast cancer should undergo genetic testing for mutations in known breast cancer predisposition genes, including BRCA1 and BRCA2, a Mayo Clinic-led study has found. The findings come from ...

Study identifies new potential treatment option for triple negative breast cancer

May 21, 2018
In a recent study published in the Journal of Clinical Investigation, Mayo Clinic researchers identified that an FDA drug approved for myelodysplastic syndrome may be useful to treat triple-negative breast cancer, which is ...

Genetic predisposition to breast cancer due to non-brca mutations in ashkenazi Jewish women

July 20, 2017
Genetic mutations in BRCA1 and BRCA2 increase the risk of breast and ovarian cancer in Ashkenazi Jewish women. A new article published by JAMA Oncology examines the likelihood of carrying another cancer-predisposing mutation ...

Busting myths surrounding cancer and genetic testing

April 13, 2018
(HealthDay)—While only 5 percent to 10 percent of cancers are caused by an inherited gene mutation, genetic testing may benefit people with a strong history of family cancer, an expert in genetics suggests.

Genetic targets to chemo-resistant breast cancer identified

October 3, 2017
Research led by Dr. Carlos Arteaga, Director of the Harold C. Simmons Comprehensive Cancer Center, has identified potential targets for treatment of triple negative breast cancer, the most aggressive form of breast cancer.

Recommended for you

Scientists discover new method of diagnosing cancer with malaria protein

August 17, 2018
In a spectacular new study, researchers from the University of Copenhagen have discovered a method of diagnosing a broad range of cancers at their early stages by utilising a particular malaria protein that sticks to cancer ...

Developing an on-off switch for breast cancer treatment

August 17, 2018
T-cells play an important role in the body's immune system, and one of their tasks is to find and destroy infection. However, T-cells struggle to identify solid, cancerous tumors in the body. A current cancer therapy is using ...

Pregnant? Eating broccoli sprouts may reduce child's chances of breast cancer later in life

August 16, 2018
Researchers at the University of Alabama at Birmingham have found that a plant-based diet is more effective in preventing breast cancer later in life for the child if the mother consumed broccoli while pregnant. The 2018 ...

Three scientists share $500,000 prize for work on cancer therapy

August 15, 2018
Tumors once considered untreatable have disappeared and people previously given months to live are surviving for decades thanks to new therapies emerging from the work of three scientists chosen to receive a $500,000 medical ...

PARP inhibitor improves progression-free survival in patients with advanced breast cancers

August 15, 2018
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over ...

New clues into how 'trash bag of the cell' traps and seals off waste

August 15, 2018
The mechanics behind how an important process within the cell traps material before recycling it has puzzled scientists for years. But Penn State researchers have gained new insight into how this process seals off waste, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.